Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
Details : MCLA-158 (petosemtamab), a Biclonics® low-fucose human full-length IgG1 antibody targeting the EGFR, being developed for metastatic colorectal cancer in combination with pembrolizumab.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $400.2 million
Deal Type : Public Offering
Merus Announces Pricing of Upsized Public Offering of Common Shares
Details : Merus will use the proceeds to advance the clinical development of its candidates, including MCLA-158 (petosemtamab), a Biclonics® low-fucose human full-length IgG1 antibody targeting the EGFR.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $400.2 million
Deal Type : Public Offering
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merus' Petosemtamab and Pembrolizumab Show Strong Response in 1L r/m HNSCC
Details : MCLA-158 (petosemtamab) is a IgG1 bispecific antibody targeting EGFR and LGR5. It is being investigated as a treatment for recurrent or metastatic HNSCC in combination with pembrolizumab.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $400.0 million
Deal Type : Public Offering
Merus N.V. Announces Proposed Public Offering of Common Shares
Details : The net proceeds will be used to advance the clinical development of MCLA-158 (petosemtamab), an EGFR inhibitor. It is being evaluated for the treatment of head and neck and colorectal cancer.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $400.0 million
Deal Type : Public Offering
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
Details : MCLA-158 (petosemtamab) full-length IgG1 bispecific antibody targeting EGFR and LGR5. It is being evaluated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Petosemtamab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petosemtamab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $150.0 million
Deal Type : Public Offering
Merus Announces Pricing of Public Offering of Common Shares
Details : Merus currently intends to use the net proceeds to advance the clinical development of its product candidates including, MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA).
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Undisclosed
September 08, 2023
Lead Product(s) : Petosemtamab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Jefferies
Deal Size : $150.0 million
Deal Type : Public Offering
Lead Product(s) : MesoPher,Mitazalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MesoPher (Autologous Tumor Lysate-Loaded Dendritic Cell) is comprised of autologous patient DCs loaded with “PheraLys” – Amphera’s allogeneic lysate of mesothelioma cell lines and being developed for pancreatic cancer.
Product Name : MesoPher
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : MesoPher,Mitazalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petosemtamab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Petosemtamab, or MCLA-158, is a human IgG1 Biclonics® designed to bind to cancer cells expressing EGFR and leucine-rich repeat-containing G protein-coupled receptor 5. It is being investigated for head and neck squamous cell carcinoma.
Product Name : MCLA-158
Product Type : Antibody
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Petosemtamab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAVA-1207
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
Details : LAVA-1207 is a Gammabody™ that conditionally activates Vgamma9 Vdelta2 T cells upon crosslinking to PSMA to trigger the potent and preferential killing of PSMA-positive tumor cells, including metastatic castration-resistant prostate cancer.
Product Name : LAVA-1207
Product Type : Antibody
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : LAVA-1207
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MCLA-129
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MCLA-129 is a fully human IgG1 Biclonics® bispecific antibody that binds to EGFR and c-MET and is being investigated in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
Product Name : MCLA-129
Product Type : Antibody
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : MCLA-129
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable